574 related articles for article (PubMed ID: 12847521)
1. Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse.
Lu QL; Mann CJ; Lou F; Bou-Gharios G; Morris GE; Xue SA; Fletcher S; Partridge TA; Wilton SD
Nat Med; 2003 Aug; 9(8):1009-14. PubMed ID: 12847521
[TBL] [Abstract][Full Text] [Related]
2. Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping.
Goyenvalle A; Vulin A; Fougerousse F; Leturcq F; Kaplan JC; Garcia L; Danos O
Science; 2004 Dec; 306(5702):1796-9. PubMed ID: 15528407
[TBL] [Abstract][Full Text] [Related]
3. Intraperitoneal administration of phosphorothioate antisense oligodeoxynucleotide against splicing enhancer sequence induced exon skipping in dystrophin mRNA expressed in mdx skeletal muscle.
Takeshima Y; Yagi M; Wada H; Matsuo M
Brain Dev; 2005 Oct; 27(7):488-93. PubMed ID: 16198206
[TBL] [Abstract][Full Text] [Related]
4. Induction of dystrophin expression by exon skipping in mdx mice following intramuscular injection of antisense oligonucleotides complexed with PEG-PEI copolymers.
Williams JH; Sirsi SR; Latta DR; Lutz GJ
Mol Ther; 2006 Jul; 14(1):88-96. PubMed ID: 16488666
[TBL] [Abstract][Full Text] [Related]
5. Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles.
Lu QL; Rabinowitz A; Chen YC; Yokota T; Yin H; Alter J; Jadoon A; Bou-Gharios G; Partridge T
Proc Natl Acad Sci U S A; 2005 Jan; 102(1):198-203. PubMed ID: 15608067
[TBL] [Abstract][Full Text] [Related]
6. Towards a therapeutic inhibition of dystrophin exon 23 splicing in mdx mouse muscle induced by antisense oligoribonucleotides (splicomers): target sequence optimisation using oligonucleotide arrays.
Graham IR; Hill VJ; Manoharan M; Inamati GB; Dickson G
J Gene Med; 2004 Oct; 6(10):1149-58. PubMed ID: 15386737
[TBL] [Abstract][Full Text] [Related]
7. Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology.
Alter J; Lou F; Rabinowitz A; Yin H; Rosenfeld J; Wilton SD; Partridge TA; Lu QL
Nat Med; 2006 Feb; 12(2):175-7. PubMed ID: 16444267
[TBL] [Abstract][Full Text] [Related]
8. Induced dystrophin exon skipping in human muscle explants.
McClorey G; Fall AM; Moulton HM; Iversen PL; Rasko JE; Ryan M; Fletcher S; Wilton SD
Neuromuscul Disord; 2006 Oct; 16(9-10):583-90. PubMed ID: 16919955
[TBL] [Abstract][Full Text] [Related]
9. Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD.
McClorey G; Moulton HM; Iversen PL; Fletcher S; Wilton SD
Gene Ther; 2006 Oct; 13(19):1373-81. PubMed ID: 16724091
[TBL] [Abstract][Full Text] [Related]
10. Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy.
Aartsma-Rus A; Janson AA; van Ommen GJ; van Deutekom JC
BMC Med Genet; 2007 Jul; 8():43. PubMed ID: 17612397
[TBL] [Abstract][Full Text] [Related]
11. In vivo comparison of 2'-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping.
Heemskerk HA; de Winter CL; de Kimpe SJ; van Kuik-Romeijn P; Heuvelmans N; Platenburg GJ; van Ommen GJ; van Deutekom JC; Aartsma-Rus A
J Gene Med; 2009 Mar; 11(3):257-66. PubMed ID: 19140108
[TBL] [Abstract][Full Text] [Related]
12. Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligonucleotide.
Fletcher S; Honeyman K; Fall AM; Harding PL; Johnsen RD; Wilton SD
J Gene Med; 2006 Feb; 8(2):207-16. PubMed ID: 16285002
[TBL] [Abstract][Full Text] [Related]
13. By-passing the nonsense mutation in the 4 CV mouse model of muscular dystrophy by induced exon skipping.
Mitrpant C; Fletcher S; Iversen PL; Wilton SD
J Gene Med; 2009 Jan; 11(1):46-56. PubMed ID: 19006096
[TBL] [Abstract][Full Text] [Related]
14. Skipping multiple exons of dystrophin transcripts using cocktail antisense oligonucleotides.
Echigoya Y; Yokota T
Nucleic Acid Ther; 2014 Feb; 24(1):57-68. PubMed ID: 24380394
[TBL] [Abstract][Full Text] [Related]
15. Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer.
Wu B; Moulton HM; Iversen PL; Jiang J; Li J; Li J; Spurney CF; Sali A; Guerron AD; Nagaraju K; Doran T; Lu P; Xiao X; Lu QL
Proc Natl Acad Sci U S A; 2008 Sep; 105(39):14814-9. PubMed ID: 18806224
[TBL] [Abstract][Full Text] [Related]
16. Bioinformatic and functional optimization of antisense phosphorodiamidate morpholino oligomers (PMOs) for therapeutic modulation of RNA splicing in muscle.
Popplewell LJ; Graham IR; Malerba A; Dickson G
Methods Mol Biol; 2011; 709():153-78. PubMed ID: 21194027
[TBL] [Abstract][Full Text] [Related]
17. Electroporation of corrective nucleic acids (CNA) in vivo to promote gene correction in dystrophic muscle.
Kapsa RM; Wong SH; Quigley AF
Methods Mol Biol; 2008; 423():405-19. PubMed ID: 18370218
[TBL] [Abstract][Full Text] [Related]
18. DMD pseudoexon mutations: splicing efficiency, phenotype, and potential therapy.
Gurvich OL; Tuohy TM; Howard MT; Finkel RS; Medne L; Anderson CB; Weiss RB; Wilton SD; Flanigan KM
Ann Neurol; 2008 Jan; 63(1):81-9. PubMed ID: 18059005
[TBL] [Abstract][Full Text] [Related]
19. Splicing intervention for Duchenne muscular dystrophy.
McClorey G; Fletcher S; Wilton S
Curr Opin Pharmacol; 2005 Oct; 5(5):529-34. PubMed ID: 16085461
[TBL] [Abstract][Full Text] [Related]
20. Gene delivery to dystrophic muscle.
Wells KE; McMahon J; Foster H; Ferrer A; Wells DJ
Methods Mol Biol; 2008; 423():421-31. PubMed ID: 18370219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
